The Latest Breaking News from GSK

A vaccine against tuberculosis has never been closer to reality. But development slowed due to corporate interests

The World Health Organization has authorized a second malaria vaccine in a decision that could offer countries a cheaper and more effective option than the world’s first shot against the parasitic disease

The stock market’s gain this year, 17% based on the S&P 500, has some investors thinking that equities are overvalued.

The aging global population and the growing demand for drugs and therapies to treat chronic diseases are boosting the long-term prospects of the pharmaceutical industry. Amid this backdrop, value investors could consider buying fundamentally strong pharma stocks GSK plc (GSK), Horizon Therapeutics (HZNP), and Neurocrine Biosciences (NBIX), as they are…

The Medicines and Healthcare products Regulatory Agency (MHRA) approved GSK’s jab, known as Arexvy, for use among older adults in July.

While surging interest rates have taken a bite out of earnings, some companies have broken through the headwinds.

He bills himself as an iconoclast ready to shake up the Republican Party after making millions trying to do the same in the biotech industry.

There are now RSV vaccines approved for older adults and for pregnant people, and antibody shots (not vaccines) available for babies. What's the difference?

With the advent of advanced medications and the increasing need for personalized treatments, the pharmaceutical industry looks well-poised for long-term growth. Therefore, it could be worth looking into three fundamentally sound pharma stocks, Pfizer (PFE), Sanofi (SNY), and GSK plc (GSK), that are offering significant value. Read more….